![Sample our Bioscience journals, sign in here to start your access, Latest two full volumes FREE to you for 14 days]({"type":"image" , "src" : "/sda/5925/TOC-Subject-Sample-2021-Bioscience.jpg"})
Abstract
Patients with breast cancer that becomes resistant to taxanes and anthracyclines experience considerable morbidity and mortality. The Food and Drug Administration has approved the use of ixabepilone for the treatment of patients with locally advanced or metastatic breast cancer that is refractory or resistant to taxanes and anthracyclines. The purpose of this review is to summarize the evidence from published studies on the pharmacological data and clinical activity of ixabepilone in patients with breast cancer. The conclusion of this review is that ixabepilone demonstrated a high efficacy in combination with capecitabine and as a single agent in breast cancer refractory to taxanes and anthracyclines. The clinical activity of ixabepilone combined with bevacizumab for advanced breast cancer was very promising.
Acknowledgements
We want to thank Brenda McNaughton from Breast Medical Oncology Department and Stephanie P. Deming, Scientific Editor, from Scientific Publications MD Anderson Cancer Center for editorial assistance.
Primary funding source: Nellie B. Connally Breast Cancer Fund.
Declaration of interest: G. N. Hortobagyi has worked with Genentech, Novartis, Merck, and Sanofi Aventis. V. Valero has worked with Bristol-Myers Squibb.